Study: Blood pressure med combo cuts vEDS arterial events in half
Two years of daily irbesartan, a long-acting oral blood pressure medication, reduced the risk of severe arterial events by 50% in adults with vascular Ehlers-Danlos syndrome (vEDS). That’s according to the results of the Phase 3 ARCADE (NCT02597361) trial, which tested the medicine on a background of celiprolol,…